Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. [electronic resource]
Producer: 20210319Description: 1175-1183 p. digitalISSN:- 1600-0641
- Antineoplastic Agents -- administration & dosage
- Carcinoma, Hepatocellular -- drug therapy
- Dose-Response Relationship, Drug
- Drug-Related Side Effects and Adverse Reactions -- etiology
- Duration of Therapy
- Female
- Humans
- Italy -- epidemiology
- Learning Curve
- Liver Neoplasms -- drug therapy
- Male
- Medication Therapy Management -- statistics & numerical data
- Middle Aged
- No-Observed-Adverse-Effect Level
- Off-Label Use
- Practice Patterns, Physicians'
- Sorafenib -- administration & dosage
- Survival Analysis
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.